{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:08:34Z","timestamp":1793398114511,"version":"4.5.0"},"reference-count":332,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondazione ARPA","award":["2016_2"],"award-info":[{"award-number":["2016_2"]}]},{"name":"Progetti di Ricerca di Ateneo","award":["PRA 2015_0085"],"award-info":[{"award-number":["PRA 2015_0085"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pharmthera.2018.06.012","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T16:31:00Z","timestamp":1529944260000},"page":"20-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"special_numbering":"C","title":["Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences"],"prefix":"10.1016","volume":"192","author":[{"given":"Stefano","family":"Aringhieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Kolachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Verdesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Cini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni U.","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.06.012_bb0005","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","article-title":"Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders","volume":"9","author":"Abbas","year":"2008","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0015","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response\u2014A double-blind PET study in schizophrenia","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0020","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/syn.20109","article-title":"Modulation of dopamine release by striatal 5-HT2C receptors","volume":"55","author":"Alex","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0030","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/FPC.0b013e3283659a94","article-title":"CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment","volume":"23","author":"Almoguera","year":"2013","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.jcp.0000222513.63767.de","article-title":"A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia","volume":"26","author":"Alvarez","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex","volume":"14","author":"Amarg\u00f3s-Bosch","year":"2004","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M","article-title":"Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration","volume":"60","author":"Angelucci","year":"2000","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0055","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1017\/S1461145713001466","article-title":"Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor","volume":"17","author":"Aoyama","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0006-8993(94)91052-9","article-title":"Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes","volume":"649","author":"Ariano","year":"1994","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.euroneuro.2017.02.005","article-title":"Clozapine as the most efficacious antipsychotic for activating ERK 1\/2 kinases: Role of 5-HT2A receptor agonism","volume":"27","author":"Aringhieri","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)37013-2","article-title":"Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro","volume":"283","author":"Arvanov","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jphs.2015.01.007","article-title":"Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range","volume":"127","author":"Baba","year":"2015","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0080","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine. A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0085","article-title":"Pathophysiology of drug induced weight and metabolic effects: Findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo","volume":"1","author":"Ballon","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coph.2014.12.004","article-title":"The NMDA receptor \u2018glycine modulatory site\u2019 in schizophrenia: d-Serine, glycine, and beyond","volume":"20","author":"Balu","year":"2015","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0095","first-page":"45","article-title":"Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle","volume":"62","author":"Basile","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s004060050039","article-title":"Clozapine efficacy in tardive dyskinesia in schizophrenic patients","volume":"248","author":"Bassitt","year":"1998","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnmol.2011.00038","article-title":"Beyond cAMP: The regulation of Akt and GSK3 by dopamine receptors","volume":"4","author":"Beaulieu","year":"2011","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0115","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.15-12-07821.1995","article-title":"Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain","volume":"15","author":"Bergson","year":"1995","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0120","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm9910122","article-title":"N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists\/5-HT(1A) partial agonists with potential as atypical antipsychotic agents","volume":"42","author":"Birch","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0125","first-page":"S365","article-title":"Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia","volume":"41S","author":"Bitter","year":"2017","journal-title":"European Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0130","series-title":"Muscarinic Receptors. Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-23274-9_8","article-title":"Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions","volume":"vol. 208","author":"Bolbecker","year":"2012"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2045125316637570","article-title":"Multiple D2 heteroreceptor complexes: New targets for treatment of schizophrenia","volume":"6","author":"Borroto-Escuela","year":"2016","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbrc.2010.09.110","article-title":"Dopamine D2 and 5-hydroxytryptamine 5-HT(\u2082A) receptors assemble into functionally interacting heteromers","volume":"401","author":"Borroto-Escuela","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbrc.2010.12.083","article-title":"Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions","volume":"404","author":"Borroto-Escuela","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-2999(95)00639-7","article-title":"Pharmacology of muscarinic acetylcholine receptor subtypes (m1\u2013m5): high throughput assays in mammalian cells","volume":"295","author":"Br\u00e4uner-Osborne","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0155","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbr.2013.01.035","article-title":"Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats","volume":"244","author":"de Bruin","year":"2013","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia-results from the phase III Flashlyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0170","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0175","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0185","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1471-4159.2009.06078.x","article-title":"Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells","volume":"109","author":"Cabello","year":"2009","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.euroneuro.2014.12.002","article-title":"The atypical antipsychotic clozapine selectively inhibits interleukin 8 (IL-8)-induced neutrophil chemotaxis","volume":"25","author":"Capannolo","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0028-3908(98)00051-3","article-title":"Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats","volume":"37","author":"Carasso","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.6","article-title":"Chemistry-based molecular signature underlying the atypia of clozapine","volume":"7","author":"Cardozo","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/1570159X15666170518151127","article-title":"Dopamine D2 receptors dimers: How can we pharmacologically target them?","volume":"16","author":"Carli","year":"2018","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0210","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacologica et Toxicologica (Copenh)"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","article-title":"The muscarinic system, cognition and schizophrenia","volume":"55","author":"Carruthers","year":"2015","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0225","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0235","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1152\/jn.2002.87.5.2324","article-title":"Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex","volume":"87","author":"Chen","year":"2002","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0240","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-009-0255-4","article-title":"Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia","volume":"116","author":"Chertkow","year":"2009","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0245","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainres.2017.09.006","article-title":"Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse","volume":"1676","author":"Chikama","year":"2017","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-8993(02)03215-8","article-title":"Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration","volume":"954","author":"Chlan-Fourney","year":"2002","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0260","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.npp.1300262","article-title":"SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile","volume":"28","author":"Claustre","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0275","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.biopsych.2006.12.005","article-title":"Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia","volume":"62","author":"Corti","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0280","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00023210-200216030-00007","article-title":"Spotlight on amisulpride in schizophrenia","volume":"16","author":"Curran","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0290","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/eip.12230","article-title":"Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis","volume":"10","author":"Curtis","year":"2016","journal-title":"Early Intervetion in Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/schbul\/22.4.577","article-title":"Positive and negative symptoms: Is their change related?","volume":"22","author":"Czobor","year":"1996","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0300","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0305","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-003-0812-1","article-title":"Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat","volume":"110","author":"Dawson","year":"2003","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0361-9230(02)00967-X","article-title":"Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist","volume":"59","author":"Dawson","year":"2003","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0315","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.2174\/1381612822666160701084447","article-title":"The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders","volume":"22","author":"De Berardis","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0320","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","article-title":"Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens","volume":"24","author":"De Deurwaerd\u00e8re","year":"2004","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","article-title":"Noradrenaline and Parkinson's disease","volume":"5","author":"Delaville","year":"2011","journal-title":"Frontiers in Systems Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0335","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cercor\/bhv227","article-title":"Activation of muscarinic M1 acetylcholine receptors induces long-term potentiation in the hippocampus","volume":"26","author":"Dennis","year":"2016","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.euroneuro.2003.09.002","article-title":"Atypical antipsychotics and the relevance of glutamate and serotonin","volume":"14","author":"van der Heijden","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis","volume":"70","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0350","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s002130000503","article-title":"Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients","volume":"152","author":"Dettling","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0355","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.mp.4000904","article-title":"Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex","volume":"6","author":"Devoto","year":"2001","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0360","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1471-4159.2003.02239.x","article-title":"Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex","volume":"88","author":"Devoto","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0365","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0165-6147(00)01688-6","article-title":"Role of 5-HT(2C) receptors in the control of central dopamine function","volume":"22","author":"Di Matteo","year":"2001","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0370","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0306-4522(94)00527-C","article-title":"Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain","volume":"65","author":"Diaz","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.brainres.2009.08.032","article-title":"Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex","volume":"1298","author":"Dissanayake","year":"2009","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0380","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0006-8993(00)02062-X","article-title":"Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area","volume":"864","author":"Doherty","year":"2000","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0390","first-page":"581","article-title":"Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization\u2014A working hypothesis","volume":"60","author":"Dziedzicka-Wasylewska","year":"2008","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0395","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fpsyt.2017.00066","article-title":"Effects of antipsychotic administration on brain glutamate in schizophrenia: A systematic review of longitudinal 1H-MRS studies","volume":"8","author":"Egerton","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0400","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1517\/14656566.2012.709235","article-title":"Clozapine for the treatment of schizophrenia","volume":"13","author":"Fakra","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0405","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: Incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0410","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.euroneuro.2008.05.001","article-title":"The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine","volume":"18","author":"Faron-G\u00f3recka","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0415","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1096\/fasebj.9.8.7768353","article-title":"Muscarinic acetylcholine receptors: Signal transduction through multiple effectors","volume":"9","author":"Felder","year":"1995","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1476-5381.2009.00152.x","article-title":"Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors","volume":"157","author":"Ferrada","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0425","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/mol.107.043885","article-title":"Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization","volume":"74","author":"Fiorentini","year":"2008","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41537-017-0035-3","article-title":"Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis","volume":"3","author":"Fournier","year":"2017","journal-title":"NPJ Schizophrenia"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0435","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0440","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","article-title":"Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress","volume":"15","author":"Fumagalli","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.euroneuro.2008.09.001","article-title":"Antipsychotic drugs modulate Arc expression in the rat brain","volume":"19","author":"Fumagalli","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0460","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/00001756-200409150-00022","article-title":"Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801","volume":"15","author":"Fumagalli","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/JMN:26:2-3:209","article-title":"Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function","volume":"26","author":"Fuxe","year":"2005","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0470","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.brainresrev.2007.11.007","article-title":"Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology","volume":"58","author":"Fuxe","year":"2008","journal-title":"Brain Research Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.neuro.27.070203.144206","article-title":"Desensitization of G protein-coupled receptors and neuronal functions","volume":"27","author":"Gainetdinov","year":"2004","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0480","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000357682","article-title":"Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats","volume":"93","author":"Galloway","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0485","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40263-017-0442-z","article-title":"Cariprazine: A review in schizophrenia","volume":"31","author":"Garnock-Jones","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0490","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00210-014-1080-3","article-title":"Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex","volume":"388","author":"Gigout","year":"2015","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0495","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.01.036","article-title":"Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems","volume":"488","author":"Giorgetti","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0505","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0510","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0022-3565(25)12143-5","volume":"275","author":"Gobert","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0515","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamapsychiatry.2014.257","article-title":"Bitopertin: The good news and bad news","volume":"71","author":"Goff","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0520","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.96.18.10483","article-title":"Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice","volume":"96","author":"Gomeza","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001347","article-title":"Circadian-related heteromerization of adrenergic and dopamine D4 receptors modulates melatonin synthesis and release in the pineal gland","volume":"10","author":"Gonz\u00e1lez","year":"2012","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0530","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mp.2011.93","article-title":"Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain","volume":"17","author":"Gonz\u00e1lez","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0535","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Gr\u00fcnder","year":"2009","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0545","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.npp.1300931","article-title":"The striatal and extrastriatal D2\/D3 receptor-binding profile of clozapine in patients with schizophrenia","volume":"31","author":"Gr\u00fcnder","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0550","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2478\/acph-2014-0036","article-title":"Therapeutic drug monitoring of atypical antipsychotic drugs","volume":"64","author":"Grundmann","year":"2014","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0555","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0560","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/mol.114.093096","article-title":"Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: The dopamine D1-D3 receptor heterotetramer","volume":"86","author":"Guitart","year":"2014","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0565","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-007-0450-x","article-title":"Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients","volume":"64","author":"Gunes","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0570","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0022-3565(24)38173-X","article-title":"Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja","volume":"289","author":"Gurevich","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0575","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0580","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","article-title":"Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine","volume":"34","author":"Hagger","year":"1993","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0585","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-8993(96)01131-6","article-title":"Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635","volume":"745","author":"Hall","year":"1997","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0590","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1460-9568.2008.06029.x","article-title":"Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons","volume":"27","author":"Henny","year":"2008","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0595","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0600","doi-asserted-by":"crossref","first-page":"27109","DOI":"10.1074\/jbc.M604390200","article-title":"Serotonin 5-HT2C receptor homodimer biogenesis in the endoplasmic reticulum: Real-time visualization with confocal fluorescence resonance energy transfer","volume":"281","author":"Herrick-Davis","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0610","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0615","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0620","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: An update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0625","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: Roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0630","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.pharmthera.2005.12.001","article-title":"What has been learnt from study of dopamine receptors in Parkinson's disease?","volume":"111","author":"Hurley","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0635","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2011.11.018","article-title":"Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration","volume":"37","author":"Hwang","year":"2012","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0640","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0645","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187152409788452036","article-title":"Histamine H3-receptor inverse agonists as novel antipsychotics","volume":"9","author":"Ito","year":"2009","journal-title":"Central Nervous System Agents in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0650","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3928\/02793695-20140421-01","article-title":"The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications","volume":"52","author":"Jacobowitz","year":"2014","journal-title":"Journal of Psychosocial Nursing and Mental Health Servecs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0655","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2015.01.041","article-title":"A Phase II study of a histamine H\u2083 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy","volume":"164","author":"Jarskog","year":"2015","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0660","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-018-0042-4","article-title":"Determinants of treatment response in first-episode psychosis: An 18F-DOPA PET study","author":"Jauhar","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0665","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.npp.1300313","article-title":"Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor\/glycine-site agonists","volume":"29","author":"Javitt","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0670","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0675","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0680","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1192\/bjpo.bp.115.000927","article-title":"Antipsychotics for the management of psychosis in Parkinson's disease: Systematic review and meta-analysis","volume":"1","author":"Jethwa","year":"2015","journal-title":"BJPsych Open"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0685","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","article-title":"Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6","volume":"20","author":"Kakihara","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0690","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.162","article-title":"Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia","volume":"7","author":"Kannan","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0695","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0700","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0705","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/npp.2011.249","article-title":"Clozapine reverses phencyclidine-induced desynchronization of prefrontal cortex through a 5-HT(1A) receptor-dependent mechanism","volume":"37","author":"Kargieman","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0710","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.0704848104","article-title":"Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine","volume":"104","author":"Kargieman","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0715","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0720","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1074\/jbc.M111.301820","article-title":"Cell contact-dependent functional selectivity of \u03b22-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation","volume":"287","author":"Kaya","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0725","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0730","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0735","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1476-5381.2012.02223.x","article-title":"New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2","volume":"168","author":"Kenakin","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0740","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS570>3.0.CO;2-8","article-title":"The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease","volume":"16","author":"Kennedy","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0745","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0750","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4306\/pi.2017.14.4.383","article-title":"Neuroprotection in schizophrenia and its therapeutic implications","volume":"14","author":"Kim","year":"2017","journal-title":"Psychiatry Investigation"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0755","first-page":"S222","article-title":"A phase I open label safety and tolerability study of SEP-363856, a novel non-D2 mechanism of action molecule, in patients with schizophrenia","volume":"41","author":"Koblan","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0760","first-page":"1","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2011","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0765","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00406-006-0661-7","article-title":"Neuroleptic drugs in the human brain: Clinical impact of persistence and region-specific distribution","volume":"256","author":"Kornhuber","year":"2006","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0770","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Molecular Brain"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0775","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0780","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0785","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","article-title":"Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens","volume":"288","author":"Kuroki","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0790","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jneumeth.2006.03.017","article-title":"Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography\/tandem mass spectrometry without anti-cholinesterases","volume":"157","author":"Lacroix","year":"2006","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0795","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/syn.10288","article-title":"5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex","volume":"51","author":"Lacroix","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0800","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s007020050091","article-title":"Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia","volume":"105","author":"Lahti","year":"1998","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0805","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D\u2082 receptor occupancy for doses of 8 antipsychotics: A meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0810","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","article-title":"Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor","volume":"70","author":"Lane","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0815","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2007.04.038","article-title":"Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study","volume":"63","author":"Lane","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0820","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbr.2009.11.037","article-title":"Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: Implications for neuropsychiatric disorders","volume":"208","author":"Lauzon","year":"2010","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0825","article-title":"Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease","author":"Lebois","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0830","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/pcn.12270","article-title":"Tardive dyskinesia (syndrome): Current concept and modern approaches to its management","volume":"69","author":"Lerner","year":"2015","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0835","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0840","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0845","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0850","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0855","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1523\/JNEUROSCI.20-11-04011.2000","article-title":"Intracellular modulation of NMDA receptor function by antipsychotic drugs","volume":"20","author":"Leveque","year":"2000","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0860","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1073\/pnas.89.17.8155","article-title":"Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin","volume":"89","author":"L\u00e9vesque","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0870","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2006.11.060","article-title":"5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus","volume":"1134","author":"Li","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0875","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2008.08.009","article-title":"Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine","volume":"596","author":"Li","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0880","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00207459109082032","article-title":"Animal models of amphetamine psychosis: Neurotransmitter release from rat brain slices","volume":"60","author":"Lillrank","year":"1991","journal-title":"The International Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0890","first-page":"32297","article-title":"Sodium benzoate, a d-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: A randomized, double-blind","volume":"S0006-3223","author":"Lin","year":"2017","journal-title":"Placebo-Controlled Trial. Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0895","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1460-9568.2001.01633.x","article-title":"BDNF mRNA expression in rat hippocampus and prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs","volume":"14","author":"Lipska","year":"2001","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0900","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41598-017-02884-w","article-title":"Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats","volume":"7","author":"Liu","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0905","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature","volume":"147","author":"Lopez","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0910","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.npp.1301356","article-title":"Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat","volume":"32","author":"L\u00f3pez-Gil","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0915","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/PL00005075","article-title":"Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907","volume":"356","author":"L\u00f3pez-Gim\u00e9nez","year":"1997","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0920","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1385\/JMN:27:1:043","article-title":"Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K\/AKT, ERK, and pertussis toxin-sensitive pathways","volume":"27","author":"Lu","year":"2005","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2011.03.038","article-title":"Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor","volume":"659","author":"\u0141ukasiewicz","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0930","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbamcr.2010.08.010","article-title":"Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors","volume":"1803","author":"\u0141ukasiewicz","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0935","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2009.10.001","article-title":"Dopamine D2-D3 receptor heteromers: Pharmacological properties and therapeutic significance","volume":"10","author":"Maggio","year":"2010","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0940","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/B978-0-12-391862-8.00016-8","article-title":"Experimental strategies for studying G protein-coupled receptor homo- and heteromerization with radioligand binding and signal transduction methods","volume":"521","author":"Maggio","year":"2013","journal-title":"Methods in Enzymology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0945","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.euroneuro.2014.09.016","article-title":"Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation","volume":"25","author":"Maggio","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0950","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1590\/1516-4446-2016-1993","article-title":"Superwellness Program: A cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs","volume":"39","author":"Magni","year":"2017","journal-title":"Revista Brasileira de Psiquiatria"},{"issue":"8","key":"10.1016\/j.pharmthera.2018.06.012_bb0955","first-page":"42","article-title":"The role of norepinephrine and Its \u03b1-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: A systematic review","volume":"2017","author":"Maletic","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0960","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0965","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.biopsych.2004.02.003","article-title":"Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain","volume":"55","author":"Maragnoli","year":"2004","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0970","doi-asserted-by":"crossref","first-page":"26016","DOI":"10.1074\/jbc.M710349200","article-title":"Identification of dopamine D1\u2013D3 receptor heteromers. Indications for a role of synergistic D1\u2013D3 receptor interactions in the striatum","volume":"283","author":"Marcellino","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0975","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.106989","article-title":"WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity","volume":"320","author":"Marquis","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0980","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.0803522105","article-title":"Antagonism of dopamine D2 receptor\/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics","volume":"105","author":"Masri","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0985","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-9964(03)00159-2","article-title":"Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients","volume":"66","author":"Mauri","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0990","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","article-title":"Long-term treatment of chronic schizophrenia with risperidone: A study with plasma levels","volume":"16","author":"Mauri","year":"2001","journal-title":"European Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb0995","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1000","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.npp.1301098","article-title":"SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): A novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug","volume":"32","author":"McCreary","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1005","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1021\/jm201420s","article-title":"Homobivalent ligands of the atypical antipsychotic clozapine: Design, synthesis, and pharmacological evaluation","volume":"55","author":"McRobb","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1010","first-page":"144","article-title":"Dopamine2 receptor occupancy and the action of clozapine: Does it make a difference to add a neuroleptic?","volume":"46","author":"Meltzer","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1176\/appi.ajp.2015.15030338","article-title":"Attention must be paid: The association of plasma clozapine\/NDMC ratio with working memory","volume":"172","author":"Meltzer","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568007024606258","article-title":"N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: A critical review","volume":"1","author":"Millan","year":"2002","journal-title":"Current Drug Targets. CNS and Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00213-005-2199-1","article-title":"N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: Novel insights and clinical perspectives","volume":"179","author":"Millan","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1070","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0028-3908(98)00078-1","article-title":"Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo","volume":"37","author":"Millan","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1075","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1460-9568.2000.00982.x","article-title":"Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: A comparison with citalopram","volume":"12","author":"Millan","year":"2000","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0022-3565(24)38153-4","article-title":"S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine","volume":"289","author":"Millan","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.acr.2014.10.002","article-title":"Regulation of ABC transporters blood-brain barrier: The good, the bad, and the ugly","volume":"125","author":"Miller","year":"2015","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: From structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1110","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuropharm.2013.10.021","article-title":"Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action","volume":"79","author":"Mocci","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2009.06.001","article-title":"Antipsychotic drug actions on gene modulation and signaling mechanisms","volume":"124","author":"Molteni","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1130","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.120","article-title":"The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression","volume":"7","author":"Morais","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1135","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1523\/JNEUROSCI.2442-16.2016","article-title":"Functional \u03bc-opioid-galanin receptor heteromers in the ventral tegmental area","volume":"37","author":"Moreno","year":"2017","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386931-9.00008-8","article-title":"G protein-coupled receptor heterocomplexes in neuropsychiatric disorders","volume":"117","author":"Moreno","year":"2013","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1145","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1150","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D3 receptor neurotransmission in cognition","volume":"23","author":"Nakajimaa","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1155","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2005.07.035","article-title":"Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo","volume":"59","author":"Navailles","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1160","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: Rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014A meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/syn.10189","article-title":"Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex","volume":"48","author":"Ninan","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bjp.0701357","article-title":"Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor","volume":"122","author":"Olianas","year":"1997","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","article-title":"Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells","volume":"20","author":"Olianas","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/pr.114.010249","article-title":"International union of basic and clinical pharmacology. XCVIII. Histamine receptors","volume":"67","author":"Panula","year":"2015","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neulet.2003.10.079","article-title":"Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol","volume":"356","author":"Parikh","year":"2004","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00213-003-1669-6","article-title":"Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine","volume":"172","author":"Parikh","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1205","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jpsychires.2008.05.010","article-title":"Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats","volume":"43","author":"Park","year":"2009","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1210","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00023210-200013030-00003","article-title":"Therapeutic drug monitoring of atypical antipsychotics","volume":"13","author":"Perry","year":"2000","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1220","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1225","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1073\/pnas.1502742112","article-title":"Elucidation of G-protein and \u03b2-arrestin functional selectivity at the dopamine D2 receptor","volume":"112","author":"Peterson","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1230","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/jm100210p","article-title":"Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia","volume":"53","author":"Pinard","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: Review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1240","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","article-title":"Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: Correlation with receptor binding","volume":"12","author":"Pompeiano","year":"1992","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1245","first-page":"33","article-title":"Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia","volume":"55","author":"Potkin","year":"1994","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1250","doi-asserted-by":"crossref","first-page":"555","DOI":"10.31887\/DCNS.2014.16.4\/jpouget","article-title":"Pharmacogenetics and outcome with antipsychotic drugs","volume":"16","author":"Pouget","year":"2014","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1471-4159.2002.00947.x","article-title":"Stimulation of 5-hydroxytryptamine (5-HT(2C)) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex","volume":"82","author":"Pozzi","year":"2002","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1260","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbrc.2008.10.044","article-title":"Roles of G protein and beta-arrestin in dopamine D2 receptor-mediated ERK activation","volume":"377","author":"Quan","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1265","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1270","doi-asserted-by":"crossref","first-page":"E587","DOI":"10.1208\/aapsj070360","article-title":"Mu opioid receptor regulation and opiate responsiveness","volume":"7","author":"Raehal","year":"2005","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: Biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nature Reviews Drug Discovovery"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","article-title":"Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor","volume":"299","author":"Rauser","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1290","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087997","article-title":"A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia","volume":"9","author":"Rizos","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1305","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00018-010-0293-y","article-title":"The dopamine D4 receptor: Biochemical and signalling properties","volume":"67","author":"Rondou","year":"2010","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1310","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/mol.116.107607","article-title":"The first negative allosteric modulator for dopamine D2 and D3 receptors, SB269652 may lead to a new generation of antipsychotic drugs","volume":"91","author":"Rossi","year":"2017","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1315","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"van Rossum","year":"1966","journal-title":"Archives Internationales de Pharmacodynamie et de Th\u00e9rapie"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1325","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1330","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.euroneuro.2016.01.001","article-title":"The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor","volume":"26","author":"Sahlholm","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1335","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1340","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0024-3205(89)90206-3","article-title":"Dopamine receptor occupancy in vivo: Measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)","volume":"45","author":"Saller","year":"1989","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1345","first-page":"11","article-title":"Laminar and cellular distribution of monoamine receptors in rat medial prefrontal cortex","author":"Santana","year":"2017","journal-title":"Frontiers in Neuroanatomy"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1350","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1355","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1756285616664300","article-title":"Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis","volume":"9","author":"Sarva","year":"2016","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1360","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00213-015-4002-2","article-title":"Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: A positron emission tomography study in healthy volunteers","volume":"232","author":"Sato","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1365","first-page":"832","article-title":"Newer oral atypical antipsychotic agents: A review","volume":"36","author":"Scarff","year":"2011","journal-title":"P & T"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BST20120250","article-title":"Enlightening G-protein-coupled receptors on the plasma membrane using super-resolution photoactivated localization microscopy","volume":"41","author":"Scarselli","year":"2013","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1375","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/febs.13577","article-title":"Revealing G-protein-coupled receptor oligomerization at the single-molecule level through a nanoscopic lens: Methods, dynamics and biological function","volume":"283","author":"Scarselli","year":"2016","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1380","doi-asserted-by":"crossref","first-page":"30308","DOI":"10.1074\/jbc.M102297200","article-title":"D2\/D3 dopamine receptor heterodimers exhibit unique functional properties","volume":"276","author":"Scarselli","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1390","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/npp.2014.38","article-title":"Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a \u03b2arrestin2-independent activation of Akt","volume":"39","author":"Schmid","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1395","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neubiorev.2014.03.009","article-title":"Modulation of behavior by the histaminergic system: Lessons from H(1)R-and H(2)R-deficient mice","volume":"42","author":"Schneider","year":"2014","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1400","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/syn.20008","article-title":"Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex","volume":"52","author":"Schwieler","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1405","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","article-title":"Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area","volume":"83","author":"Schwieler","year":"2008","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/365441a0","article-title":"Dopamine D4 receptors elevated in schizophrenia","volume":"365","author":"Seeman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1415","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.97.14.7673","article-title":"Schizophrenia: More dopamine, more D2 receptors","volume":"97","author":"Seeman","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1420","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/syn.20298","article-title":"Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus","volume":"60","author":"Seeman","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tips.2012.11.001","article-title":"Molecular and cellular analysis of human histamine receptor subtypes","volume":"34","author":"Seifert","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1430","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1435","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0893-133X(01)00400-6","article-title":"Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat","volume":"26","author":"Shirazi-Southall","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1440","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2217\/pgs.10.123","article-title":"Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: An update and meta-analysis","volume":"11","author":"Sicard","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1445","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1124\/mol.110.065755","article-title":"The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors","volume":"78","author":"Silvano","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1450","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"The British Journal of Psychiatry: the Journal of Mental Science"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1455","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1460","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D\u2083 receptor with glutamate pathways: Implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004714-198902000-00021","article-title":"Use of buspirone in the treatment of schizophrenia","volume":"9","author":"Sovner","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1470","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1475","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: A comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1480","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-018-0494-8","article-title":"Tardive dyskinesia associated with atypical antipsychotics: Prevalence, mechanisms and management strategies","volume":"32","author":"Stegmayer","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1485","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1490","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1495","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1500","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors","volume":"8","author":"Sykes","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1505","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1510","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0269881108095704","article-title":"Asenapine induces differential regional effects on serotonin receptor subtypes","volume":"24","author":"Tarazi","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1515","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0278-5846(98)00033-5","article-title":"Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs","volume":"22","author":"Tarazi","year":"1998","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1520","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0006-3223(01)01135-0","article-title":"Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats","volume":"50","author":"Tascedda","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1525","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hup.1137","article-title":"More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial","volume":"25","author":"Terevnikov","year":"2010","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1530","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/npp.2008.74","article-title":"Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum","volume":"34","author":"Thomas","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1535","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1523\/JNEUROSCI.1021-04.2004","article-title":"Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms","volume":"24","author":"Tseng","year":"2004","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1540","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuron.2012.08.037","article-title":"The fibroblast growth factor family: neuromodulation of affective behavior","volume":"76","author":"Turner","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1545","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","article-title":"M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1550","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D\u2082 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1555","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fpsyt.2017.00144","article-title":"Therapeutic potential of selectively targeting the \u03b12C-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective","volume":"8","author":"Uys","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1560","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0149-7634(99)00063-9","article-title":"Structure and function of dopamine receptors","volume":"24","author":"Vallone","year":"2000","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1565","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002194","article-title":"Cognitive impairment induced by Delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors","volume":"13","author":"Vi\u00f1als","year":"2015","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1575","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fnsys.2012.00072","article-title":"Histamine H3 receptor antagonists\/inverse agonists on cognitive and motor processes: Relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse","volume":"6","author":"Vohora","year":"2012","journal-title":"Frontiers in Systems Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1580","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.euroneuro.2015.04.014","article-title":"Cognitive enhancing agents in schizophrenia and bipolar disorder","volume":"25","author":"Vreeker","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-6606-3-25","article-title":"Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization","volume":"3","author":"Wang","year":"2010","journal-title":"Molecular Brain"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1590","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S1461145711000435","article-title":"Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: Implications for schizophrenia and its treatment","volume":"15","author":"Watson","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1595","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: Clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1600","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1605","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11096-004-1731-4","article-title":"Pharmacogenetics as a tool in the therapy of schizophrenia","volume":"27","author":"Wilffert","year":"2005","journal-title":"Pharmacy World and Science"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1610","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2004.01.013","article-title":"Effects of typical and atypical antipsychotics on human glycine transporters","volume":"71","author":"Williams","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1615","doi-asserted-by":"crossref","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling","volume":"104","author":"Wisler","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrn1033","article-title":"Human prefrontal cortex: Processing and representational perspectives","volume":"4","author":"Wood","year":"2003","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1625","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1630","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1635","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/FBP.0b013e32831c3b06","article-title":"Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat","volume":"19","author":"Woolley","year":"2008","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1640","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/cne.903510304","article-title":"Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain","volume":"351","author":"Wright","year":"1995","journal-title":"Journal of Comparative Neurology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1645","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: A critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1650","article-title":"Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia","author":"Yohn","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1655","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1660","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: A review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1665","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-2999(96)00956-9","article-title":"Muscarinic m4 receptor activation by some atypical antipsychotic drugs","volume":"321","author":"Zeng","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1670","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2013.736964","article-title":"Pharmacogenetics of antipsychotics: Recent progress and methodological issues","volume":"9","author":"Zhang","year":"2013","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1675","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1680","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/phrs.1999.0473","article-title":"Systemic chlorophenylpiperazine increases acetylcholine release from rat hippocampus-implication of 5-HT2C receptors","volume":"40","author":"Zhelyazkova-Savova","year":"1999","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1685","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","author":"Zimnisky","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.06.012_bb1690","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","article-title":"Clozapine is a potent and selective muscarinic M4 receptor agonist","volume":"269","author":"Zorn","year":"1994","journal-title":"European Journal of Pharmacology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T09:26:09Z","timestamp":1751707569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":332,"alternative-id":["S0163725818301141"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.012","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}